Brussels, Belgium

Vincent Stroobant

USPTO Granted Patents = 11 


Average Co-Inventor Count = 6.5

ph-index = 6

Forward Citations = 145(Granted Patents)


Company Filing History:


Years Active: 1999-2008

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Vincent Stroobant: Innovator in Cancer Research

Introduction

Vincent Stroobant is a prominent inventor based in Brussels, Belgium, known for his significant contributions to cancer research. With a total of 11 patents to his name, he has made remarkable strides in the field of immunology, particularly in the isolation of cytotoxic T lymphocyte (CTL) clones.

Latest Patents

Stroobant's latest patents include groundbreaking work on tumor antigens and CTL clones isolated by a novel procedure. This invention focuses on the isolation of CTL clones that are specific for proteins of the MAGE family. The process involves successive steps of stimulation and testing of lymphocytes with antigen-presenting cells that present antigens derived from various expression systems, including recombinant viruses. Additionally, he has developed antigenic peptides derived from MAGE polypeptides, which are presented by HLA-B37 molecules. These innovations provide methods for diagnosis and treatment involving these polypeptides.

Career Highlights

Throughout his career, Stroobant has worked with esteemed organizations, including the Ludwig Institute for Cancer Research Limited. His work has significantly advanced the understanding of cancer immunology and the development of targeted therapies.

Collaborations

Stroobant has collaborated with notable colleagues such as Thierry R Boon-Falleur and Pierre Van Der Bruggen, contributing to a rich exchange of ideas and research in the field.

Conclusion

Vincent Stroobant's innovative work in cancer research and his numerous patents highlight his dedication to advancing medical science. His contributions continue to impact the field of immunology and cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…